Study guide

6.2 The National Cancer Database (NCDB), RCRS Submission & CoC Quality Measures

NCRA Oncology Data Specialist ODS-C

Track your progress as you read

Finished sections get a check mark.

1 Chapter 1: The ODS-C Exam, the Oncology Data Specialist Profession & Standard Setters

1.1 ODS Exam Structure, Timing, Scoring & 2026 Testing Windows 1.2 From CTR to ODS: The Credential, Eligibility Routes & the Registrar's Role 1.3 Standard-Setting Organizations & the Manuals They Publish

2 Chapter 2: Legal Framework, HIPAA & State Reporting Laws

2.1 HIPAA Privacy Rule & the Public Health Reporting Exception 2.2 HIPAA Security Rule, Safeguards & Breach Notification 2.3 State Mandatory Cancer Reporting Laws & Statutory Authority

3 Chapter 3: Confidentiality, Release of Information, Ethics & Credential Maintenance

3.1 Patient Confidentiality Protocols & Data Access Policies 3.2 Handling Subpoenas, Discovery & Registry Immunity Statutes 3.3 NCRA Code of Ethics & ODS Credential Maintenance

4 Chapter 4: Registry Organization, Staffing & Information Systems

4.1 Types of Cancer Registries, Their Functions & Registry Operating Protocols 4.2 Registry Staffing Formulas, Time Studies & Resource Allocation 4.3 Electronic Registry Systems, Security & Disaster Recovery Planning

5 Chapter 5: Cancer Committee, Cancer Conferences & Quality Improvement

5.1 The Cancer Committee: CoC Standards 2.1–2.4, the CLP & Annual Program Activities 5.2 Multidisciplinary Cancer Case Conferences (CoC Standard 2.5) 5.3 Quality Improvement Principles & CoC Chapter 7 (Standards 7.1–7.3)

6 Chapter 6: CoC Accreditation Standards, NCDB & Data Quality

6.1 CoC Accreditation: Standards Structure, Program Categories & Accreditation Awards 6.2 The National Cancer Database (NCDB), RCRS Submission & CoC Quality Measures 6.3 Quality Control Plans & Audit Techniques (CoC Standard 6.1)

7 Chapter 7: Surveillance Programs, NAACCR Standards, Epidemiology & Statistics

7.1 National Cancer Surveillance Programs: SEER & CDC NPCR 7.2 NAACCR Data Exchange Standards, XML Data Specifications & Registry Certification 7.3 Basic Cancer Epidemiology & Descriptive Statistics 7.4 Basic Statistics: Frequency Distributions, Central Tendency, Risk Ratios & Odds Ratios 7.5 Survival Analysis, Life Tables & Presentation of Registry Data

8 Chapter 8: Medical Terminology, Anatomy & Types of Cancer

8.1 Medical Terminology & Standard Abbreviations for Cancer Abstracting 8.2 Human Anatomy & Physiology for Registrars: Tissues, Organ Walls, Subsites & Lymphatic Drainage 8.3 Types & Characteristics of Cancer: Benign vs. Malignant, Tumor Families, Spread & Precursors

9 Chapter 9: Casefinding & Reportability

9.1 Principles of Casefinding & Facility Reference Dates 9.2 Casefinding Sources: Pathology, Cytology, Disease Index & Logs 9.3 Reportability: What CoC, SEER and NPCR Require, Including Non-Malignant CNS Tumors 9.4 Ambiguous Terminology: Reportable Terms, Cytology, Discrepancies & "References of Last Resort"

10 Chapter 10: Diagnostic Procedures, Pathology Reporting, Lab Methods & Prognostic Indicators

10.1 Diagnostic & Staging Procedures: Imaging, Endoscopy, Biopsy & How They Are Coded 10.2 Pathology Reporting, CAP Cancer Protocols & Electronic Pathology (CoC Standard 5.1) 10.3 Specialty Laboratory Testing Methods: IHC, FISH, PCR/RT-PCR, NGS, Flow Cytometry & Cytogenetics 10.4 Prognostic Indicators & Site-Specific Data Items (SSDIs): HPV, KRAS, HER2 and More

11 Chapter 11: Class of Case, Key Dates & Case Identifiers

11.1 Class of Case, Date of First Contact, Date of Diagnosis & Accession/Sequence Numbers 11.2 Analytic Classes of Case (00, 10–14, 20–22): Definitions & Decision Rules 11.3 Nonanalytic Classes of Case (30–49, 99) & Why Central Registries Need Them

12 Chapter 12: Follow-Up, Vital Status & Recurrence

12.1 Follow-Up Purpose, Active & Passive Methods, and Follow-Up Source Codes 12.2 CoC Standard 6.5 Follow-Up Rates: Windows, Exclusions & Calculations 12.3 Vital Status, Date of Last Contact, Cancer Status & Death Clearance 12.4 Recurrence: Type of First Recurrence [1880], Date of First Recurrence [1860] & Recurrence vs. New Primary

13 Chapter 13: Abstracting, ICD-O-3.2 Site & Histology Coding, and Grade

13.1 The Abstracting Process: Workflow, Source Documents, Timeliness & Text Documentation 13.2 ICD-O-3.2 Topography, Primary Site Rules & Laterality 13.3 ICD-O-3.2 Morphology: Histology, Behavior & the Solid Tumor Histology Rules 13.4 Grade: The Four Time-Specific Grade Items & Site-Specific Grade Tables

14 Chapter 14: Solid Tumor Rules & Hematopoietic Coding Rules

14.1 Solid Tumor Rules: Purpose, Site Groups, Navigation & Timing Principles 14.2 Solid Tumor Rules for Breast, Colon/Rectum & Lung: The Multiple Primary Rules in Order 14.3 Solid Tumor Rules for Head & Neck, Kidney, Urinary, CNS, Melanoma & Other Sites 14.4 Hematopoietic & Lymphoid Neoplasms: Heme Manual, Heme DB, Multiple Primary & Primary Site Rules

15 Chapter 15: Staging: AJCC TNM (8th Edition & Version 9 Lung) and Summary Stage 2018

15.1 AJCC TNM Principles: Categories, Prefixes, Suffixes, General Rules & Registry Items 15.2 AJCC Time Frames: Clinical, Pathological, Post-Therapy (yc, yp), Recurrence & Autopsy 15.3 Breast Staging (AJCC 8th Edition, Part XI): T, N, M, Anatomic & Prognostic Stage Groups 15.4 Lung Staging (AJCC Version 9, 2025+): T, N2a/N2b, M1c1/M1c2 & New Stage Groups 15.5 Male Genital & Urinary Tract Staging (AJCC 8th Parts XIII–XIV): Prostate, Testis, Kidney, Bladder, Renal Pelvis & Ureter 15.6 SEER Summary Stage 2018: Codes, Timing, General Rules & Site Examples

16 Chapter 16: First-Course Treatment Coding (STORE 2025) & EDITS

16.1 Treatment Types, First Course of Treatment & Evidence-Based Guidelines (NCCN) 16.2 Surgery Coding: Rx Summ–Surg 2023 [1291], Lymph Node Surgery [1292], Other Site [1294], Margins & Reason for No Surgery 16.3 Radiation, Systemic, Transplant, Other & Palliative Treatment Coding (STORE 2025) 16.4 NAACCR EDITS, Over-ride Flags & Data Validation

6.2 The National Cancer Database (NCDB), RCRS Submission & CoC Quality Measures

Key Takeaways Explain This Topic AI

The NCDB is a joint program of the Commission on Cancer and the American Cancer Society that began in 1989, receives data from more than 1,500 CoC-accredited programs and captures about 72% of newly diagnosed U.S. cancers.

RCRS, released in September 2020, replaced the Rapid Quality Reporting System (RQRS) and the separate annual NCDB Call for Data submission; the CP3R report tool was retired and its measures moved into RCRS.

CoC Standard 6.4 requires submitting all new and updated cases to RCRS at least once each calendar month and all complete analytic cases once a year as specified by the annual Call for Data.

The cancer committee must review RCRS data and quality measure performance rates at least twice each calendar year, and these reports cannot double as the CLP's Standard 2.2 reports.

NCDB quality measures fall into accountability, quality improvement and surveillance categories, and programs compare their performance with the CoC's expected Estimated Performance Rate (EPR).

Last updated: September 2026

What the NCDB is

The National Cancer Database (NCDB) is a joint program of the Commission on Cancer and the American Cancer Society . It began in 1989 and is a nationwide oncology outcomes database built from hospital registry data. It receives data from more than 1,500 CoC-accredited programs in the United States and Puerto Rico, captures about 72% of newly diagnosed U.S. cancers at the institutional level, and holds roughly 40 million records. Accredited programs use NCDB tools to compare their care with state, regional and national patterns. Researchers use de-identified Participant User Files (PUFs) .

NCDB data are hospital-based , not population-based. They come only from accredited programs and include only analytic cases. NCDB therefore does not measure incidence. That job belongs to SEER and NPCR central registry data.

STORE notes that NCDB reporting takes place under the facility's American College of Surgeons Business Associate/Data Use Agreement . Services that share the hospital's Federal Employer Identification Number (FEIN) are generally covered by the hospital's accreditation and are reportable to NCDB.

From annual batches to RCRS

For three decades, programs submitted a year's worth of completed cases in the annual NCDB Call for Data , and some breast and colorectal measures were tracked concurrently in the Rapid Quality Reporting System (RQRS) . In September 2020 the NCDB released the Rapid Cancer Reporting System (RCRS) . RCRS replaced RQRS and the separate Call for Data submission, and the Cancer Program Practice Profile Reports (CP3R) tool was retired, with several of its measures moved into RCRS. CoC then retired Standards 6.2 (Data Submission) and 6.3 (Data Accuracy) in 2021 and made Standard 6.4 the data submission standard.

Standard 6.4: Rapid Cancer Reporting System – Data Submission

Requirement Detail

Monthly submission All new and updated cancer cases are submitted at least once each calendar month . A calendar month runs from the first day to the last day of the month.

Annual complete submission Once each calendar year, the program submits all complete analytic cases for all disease sites through RCRS, as specified by the annual Call for Data

Active participation The program participates in RCRS through the whole accreditation cycle and follows the RCRS terms and conditions

Committee review RCRS data and the required quality measure performance rates are reported to the cancer committee at least twice each calendar year and documented in the minutes

No double counting RCRS reports cannot also satisfy the CLP's NCDB presentations under Standard 2.2

The standard describes RCRS as a way for programs "to report data on patients concurrently and receive notifications of treatment expectations." Because cases are submitted while treatment is still under way, RCRS can flag patients who have not yet received expected care, such as radiation after breast-conserving surgery or adjuvant chemotherapy for stage III colon cancer, while there is still time to act. It also shows performance rates for each CoC quality measure compared with state, peer and national rates.

Which cases go to RCRS and NCDB?

Analytic cases (Class of Case 00–22 ) for tumors the CoC requires. STORE defines these.

Class of Case 00 cases are analytic, but CoC does not require them to be staged or followed.

Nonanalytic cases (Class of Case 30–99) are not required by CoC. A program may still collect them for the cancer committee or the state.

CoC quality measures

The CoC's Quality Assessment and Data Committee reviews the measure portfolio every year, adds new measures and retires those that have been "maximized." Measure specifications, evaluation years and expected performance thresholds are posted on the NCDB site and in the RCRS user library. Standard 7.1 requires the cancer committee to monitor the program's rates against the expected Estimated Performance Rate (EPR) and to act when a rate falls below it.

Measure category Meaning

Accountability Strong evidence that the care process improves outcomes; suitable for comparing and holding providers accountable

  • Quality improvement Evidence supports the process, but it is used mainly to guide internal improvement
  • Surveillance Used to monitor patterns and trends in care, without judging performance

Examples of long-standing measure concepts, with wording that shows the "considered or administered" convention:

Breast, radiation after breast-conserving surgery: radiation therapy is considered or administered within a set time after diagnosis for women under 70 treated with breast-conserving surgery.

Breast, radiation after mastectomy (MASTRT): radiation is considered or administered within 1 year (365 days) of diagnosis for women with 4 or more positive regional lymph nodes.

Colon, adjuvant chemotherapy (ACT): chemotherapy is considered or administered within 4 months (120 days) of diagnosis for patients under age 80 with AJCC stage III (lymph-node-positive) colon cancer.

Colon, 12 regional lymph nodes (12RLN): at least 12 regional lymph nodes are removed and pathologically examined for resected colon cancer.

" Considered " matters. A patient who refused recommended therapy, or for whom the physician documented a contraindication, can still meet a measure when the registry codes the reason correctly (for example, chemotherapy code 87 for refusal or 82 for contraindication). This is one reason accurate treatment coding and follow-up are quality work, not just clerical work.

The registrar's role in RCRS

Submit monthly , even for cases that are still incomplete. RCRS expects new cases to be updated as treatment is given.

Watch for treatment-expectation notifications , and find out whether the care was given elsewhere, refused, contraindicated or still pending.

Correct errors that EDITS or RCRS flag, and resubmit.

Prepare the twice-yearly report of RCRS data and measure performance for the cancer committee.

Worked example

RCRS shows 70% performance on a breast radiation measure. The ODS reviews the 18 patients who "failed" and finds that 12 received radiation at an unaffiliated center, 2 refused it, and 4 have no documentation. After obtaining the outside treatment summaries, coding the refusals with the reason-for-no-treatment codes and resubmitting, the performance rate is recalculated. Only then does the committee decide whether a real care gap remains and needs a Standard 7.3 initiative.

Loading diagram... RCRS data flow under Standard 6.4